Heron Therapeutics (HRTX) Receivables - Other (2020 - 2025)

Heron Therapeutics (HRTX) has reported Receivables - Other for 6 consecutive years, with $344000.0 the latest figure, recorded in Q4 2025.

• For the quarter ending Q4 2025, Receivables - Other rose 30.8% year-over-year to $344000.0; the trailing twelve-month figure through Dec 2025 stood at $344000.0 (up 30.8% YoY), and the FY2025 full-year result was $344000.0, up 30.8% from the prior year.
• Receivables - Other climbed to $344000.0 in Q4 2025 per HRTX's latest filing, from $263000.0 in the prior quarter.
• Across five years, Receivables - Other topped out at $6.2 million in Q4 2022 and bottomed at $245000.0 in Q4 2021.
• Historically, Receivables - Other has averaged $1.5 million across 5 years, with a median of $310000.0 in 2023.
• The sharpest annual moves came in 2022 and 2023: Receivables - Other jumped 2429.39% in 2022, then slumped 95.0% in 2023.
• Over 5 years, Receivables - Other stood at $245000.0 in 2021, then surged by 2429.39% to $6.2 million in 2022, then plunged by 95.0% to $310000.0 in 2023, then slipped by 15.16% to $263000.0 in 2024, then jumped by 30.8% to $344000.0 in 2025.
• According to Business Quant data, Receivables - Other over the past three periods registered $344000.0, $263000.0, and $310000.0 for Q4 2025, Q4 2024, and Q4 2023 respectively.